Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy by unknown
MEETING ABSTRACT Open Access
Genetic polymorphisms and ovarian cancer risk
and response to paclitaxel/cisplatin chemotherapy
Karolina Tecza1*, Jolanta Pamula-Pilat1, Zofia Kolosza2, Natalia Radlak3, Ewa Grzybowska1
From Annual Conference on Hereditary Cancers 2013
Szczecin, Poland. 26-27 September 2013
Single nucleotide polymorphisms modulate the risk of
developing ovarian cancer during lifetime. In this study we
analyzed 12 polymorphic variants and 2 deletions in PGR,
ABCB1, ABCG2, GSTT1, GSTM1, GSTP1, ATM, TP53
and ATP7B genes. Ten genetic modifications were signifi-
cantly associated with the risk of developing ovarian carci-
noma in at least one of the groups under study. PGR gene
polymorphisms’ impact on ovarian cancer risk was specific
only for the group of the BRCA1 mutation carriers, which
proves the difference in the modulation of ovarian cancer
risk between sporadic and hereditary malignancies, includ-
ing the breast-ovarian cancer group (as a cancer-prone
group). The analyses showed also the importance of
ATP7B gene in ovarian carcinogenesis, both studied var-
iants of which significantly modulated the ovarian cancer
risk in three out of four groups. Cumulative risk analysis
revealed 3 unfavorable variants that significantly increased
the risk of developing ovarian cancer, and also two favor-
able genotypes which protected against ovarian cancer.
Survival analysis for carriers of favorable versus unfavor-
able genotypes emphasized the importance of regulation
of the cell cycle and active transport of xenobiotics during
paclitaxel/cisplatin chemotherapy. The unfavorable var-
iants could facilitate carcinogenic process and once their
carriers developed malignancy, their chances of survival
were smaller. Our analyses also showed a strong gene-
dosage effect with the decrease of progression-free survival
for the carriers of two unfavorable genetic factors.
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